Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1251 to 1300 of 1372 results for patients and public

  1. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    In development [GID-TA10502] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development [GID-TA11274] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Zio XT for detecting cardiac arrhythmias

    In development [GID-MT591] Expected publication date: TBC

    Medical technologies guidance
    In development

  4. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  5. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

    Technology appraisal guidance
    Discontinued

  6. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued [GID-TA11258]

    Technology appraisal guidance
    Discontinued

  7. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

    Technology appraisal guidance
    Discontinued

  8. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

    Technology appraisal guidance
    Discontinued

  9. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  10. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    In development [GID-TA11108] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]

    In development [GID-TA11042] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. ALXN1840 for treating Wilson disease TS ID 9950

    In development [GID-TA11449] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued [GID-TA11151]

    Technology appraisal guidance
    Discontinued

  15. Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]

    In development [GID-TA11107] Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Terevalefim for treating delayed graft function after kidney transplant [ID1490]

    Discontinued [GID-TA11098]

    Technology appraisal guidance
    Discontinued

  17. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    In development [GID-TA11252] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development [GID-TA11010] Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    In development [GID-TA11255] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID6129]

    In development [GID-TA11033] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  22. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  23. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    In development [GID-TA10965] Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]

    Discontinued [GID-TA11208]

    Technology appraisal guidance
    Discontinued

  25. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued [GID-TA11173]

    Technology appraisal guidance
    Discontinued

  26. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    In development [GID-TA11421] Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    In development [GID-TA11034] Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  31. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued [GID-TA11180]

    Technology appraisal guidance
    Discontinued

  32. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    In development [GID-TA10958] Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    In development [GID-TA11026] Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    In development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    In development [GID-TA11020] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    In development [GID-TA11109] Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    In development [GID-TA10995] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    In development [GID-TA11000] Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    In development [GID-TA11204] Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    In development [GID-TA10996] Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    In development [GID-TA11004] Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    In development [GID-TA11244] Expected publication date: TBC

    Technology appraisal guidance
    In development

  46. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    In development [GID-TA11264] Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development [GID-TA10858] Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    In development [GID-TA11041] Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    In development [GID-TA11024] Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]

    In development [GID-TA11066] Expected publication date: TBC

    Technology appraisal guidance
    In development